Skip Navigation



Home » Clinical Trials » Alzheimer's Disease

Clinical Trial Details


Research Study Summary

A clinical study for patients with Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease or Huntington's Disease

Research Study Title

A Multi-Center Longitudinal Biorepository Study to Provide Biospecimens & Clinical Data From Neurological Disease Patients To Approved Pre-Clinical And Clinical Investigators for Drug & Biomarker Studies


The purpose of this research project is to collect and store blood samples and clinical data. Researchers can then use the stored samples in future studies. Through such studies, they hope to find new ways to detect, treat, and maybe even prevent or cure health problems.

To Learn more

Both Male and Female


18 to 80 Years

Overall Status


Lead Sponsor

Sanguine Biosciences


47 Months

Facility Type



Both Male and Female ages 18 Years to 80 Years

Inclusion Criteria:

  • Males and females > 18 to 80 years of age at blood draw date.

  • A diagnosis of Multiple Sclerosis, Alzheimer's, Huntington's, or Parkinson's Disease made at any time prior to blood draw. Blood draw and diagnosis at same visit is adequate.

  • The date of diagnosis of MS, Alzheimer's, Huntington's, or Parkinson's Disease is known (this date may be from the medical records or may be self-reported by the patient with approval from the Sponsor).

  • The diagnosis is confirmable in the medical record by any of the following criteria: clinical information, MRI scan (evidence of 2 or more lesions), and Lumbar Puncture.

  • Control group: Healthy donors, males and females, 18 to 80 years of age

  • Patient and control group: Subject medical records are available

  • Patient and control group: Understands the procedures and requirements of the study by providing written informed consent including consent for authorization for protected health information disclosure.

Exclusion Criteria

  • Receipt of blood products prior to study entry.

  • Known pregnancy or having given birth within the past 3 months.

  • Receipt of an investigational (unapproved) drug 30 days prior to the blood draw.

Site Locations (1)

Country State City Zip Facility and Contact
United States California Valencia 91355 Sanguine Biosciences
Carlyn Crisostomo

Carlyn Crisostomo
Principal Investigator


Carlyn Crisostomo

If you would like to learn more about participating in this research study, please email the trial contact using the form below.

Zip/Postal Code:
Please leave this field empty.

NCT ID: NCT01592552

Date Last Changed: December 11, 2013

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials. Some study summaries have been edited for clarity purposes to make them easier to understand. View more study details here.